1. Scrip
  2. >>R&D
  3. >>Clinical Trials

BioNTech Can Rival Summit In VEGF x PD-(L)1 Bispecifics

 
• By Andrew McConaghie

Summit and Akeso have established a big lead in lung cancer with ivonescimab, but BioNTech aims to make its rival, BNT327, the leader in other tumor types.

BioNTech Shutterstock
• Source: Shutterstock

Summit Therapeutics and its partner Akeso have a commanding lead in the VEGF x PD-(L)1 bispecific cancer immunotherapy field, but BioNTech is also focused on being a major contender.

Several key clinical trial readouts for their respective lead candidates, ivonescimab and BNT327, are expected in 2025 which could help both companies build their presence, illustrated

Key Takeaways
  • Summit's first Phase III readout is expected by summer, which could put ivonescimab on track for approval by early 2026

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from Therapy Areas